Skip to main content

ALT

Stock
Health Care
Biotechnology

Performance overview

ALT Price
Price Chart

Forward-looking statistics

Beta
0.76
Risk
84.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Company info

SectorHealth Care
IndustryBiotechnology
Employees64
Market cap$457.7M

Fundamentals

Enterprise value$165.6M
Revenue$20.0K
Revenue per employee—
Profit margin0.00%
Debt to equity1.12

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.26
Dividend per share—
Revenue per share$0.00
Avg trading volume (30 day)$34M
Avg trading volume (10 day)$73M
Put-call ratio—

Macro factor sensitivity

Growth-13.0
Credit+17.9
Liquidity+3.7
Inflation-17.6
Commodities-9.5
Interest Rates-3.3

Valuation

Dividend yield0.00%
PEG Ratio-3.24
Price to sales19303.47
P/E Ratio-3.24
Enterprise Value to Revenue8282.25
Price to book2.61

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day—
Ex. dividend dayJanuary 20, 2017

News

Alta Equipment (ALTG) Stock Jumps 16.1%: Will It Continue to Soar?

Alta Equipment (ALTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Investment Research (July 9, 2025)
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).

Benzinga (June 27, 2025)
Altimmune, Bit Digital, Kratos Defense & Security Solutions And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday.

Benzinga (June 26, 2025)
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%

The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research (May 9, 2025)
Final Trade: WST, BTC, GLD, ALT

The final trades of the day with the Fast Money traders.

CNBC Television (February 14, 2025)
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

CNBC (May 7, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free